Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1α and VEGF production and improves functional recovery after acute ischemia/reperfusion.

@article{Poynter2011SystemicPW,
  title={Systemic pretreatment with dimethyloxalylglycine increases myocardial HIF-1α and VEGF production and improves functional recovery after acute ischemia/reperfusion.},
  author={Jeffrey A. Poynter and Mariuxi C. Manukyan and Yue Wang and Benjamin D Brewster and Jeremy L. Herrmann and Brent R. Weil and Aaron M. Abarbanell and Daniel R. Meldrum},
  journal={Surgery},
  year={2011},
  volume={150 2},
  pages={278-83}
}
BACKGROUND Stem cells protect the heart from ischemic damage in part by the release of cytoprotective growth factors, particularly vascular endothelial growth factor (VEGF). Production of VEGF is regulated in part by levels of the transcription factor hypoxia inducible factor 1-α (HIF-1α). Dimethyloxalylglycine (DMOG) prevents the deactivation of HIF-1α and increases VEGF production. However, the effects of systemic DMOG treatment on myocardial tolerance for ischemia are unknown. We… CONTINUE READING